Representative Frank Pallone (D-NJ) (Photo by Michael Brochstein/Sipa USA)(Sipa via AP Images)

May 5, 2022 10:43 AM EDTUpdated 01:39 PM

Congress mulls softer accelerated approval reforms as part of user fee reauthorizations

Zachary Brennan

Senior Editor

Newly proposed, must-pass bipartisan legislation that pays the FDA over the next five years for its reviews of new medical products may also include new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Congress mulls softer accelerated approval reforms as part of user fee reauthorizations

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Con­gress mulls soft­er ac­cel­er­at­ed ap­proval re­forms as part of user fee reau­tho­riza­tions

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Congress mulls softer accelerated approval reforms as part of user fee reauthorizations